Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

05-102022

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

BAT7104 was designedto inhibit the PD-1/PD-L1 and CD47/SIRP-α pathways. By an “imbalanced” designwith finely tuned bindi...
03-302022

Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in Australia Evaluating BAT6026, an Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, an Anti-PD-1 Antibod

Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagepharmaceutical company, tod...
01-242022

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors

Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceuticalcompany, tod...

上一页 ···19 20 21 22 23 ··· 下一页